TG Therapeutics Ownership | Who Owns TG Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

TG Therapeutics Ownership Summary


TG Therapeutics is owned by 56.31% institutional investors, 7.23% insiders, and 36.46% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 15.02% of TGTX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.18% of its assets in TG Therapeutics shares.

TGTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTG Therapeutics56.31%7.23%36.46%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de21.85M15.02%$651.30M
Vanguard group15.84M10.89%$472.22M
Blackrock11.39M7.79%$202.60M
State street8.48M5.83%$252.79B
Clearbridge investments3.45M2.37%$102.79M
Geode capital management3.40M2.34%$101.48M
Soleus capital management3.14M2.16%$93.58M
Bank of america corp /de/2.08M1.42%$37.04M
Goldman sachs group2.05M1.41%$61.14M
Congress asset management co /ma1.92M1.32%$57.31M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
M28 capital management lp161.60K8.58%$5.84M
Soleus capital management3.14M3.45%$93.58M
Ghost tree capital500.00K2.79%$8.89M
Opaleye management535.00K2.73%$19.33M
Pandora wealth78.10K1.41%$2.33M
Penn capital management company538.12K1.28%$16.08M
Cornerstone select advisors54.09K1.12%$1.61M
Spotlight asset group82.10K1.02%$1.46M
Quantum private wealth98.91K0.86%$2.95M
Iridian asset management llc/ct75.29K0.83%$2.24M

Top Buyers

HolderShares% AssetsChange
Congress asset management co /ma1.92M0.40%1.92M
Man group1.01M0.06%868.70K
Balyasny asset management696.13K0.04%696.13K
Bnp paribas arbitrage, snc683.65K0.01%612.19K
Blackrock funding, inc. /de21.85M0.01%548.04K

Top Sellers

HolderShares% AssetsChange
Marshall wace, llp---2.05M
Deep track capital, lp---1.73M
Clearbridge investments3.45M0.08%-1.20M
Wellington management group llp60.60K0.00%-1.17M
Vestal point capital, lp---1.05M

New Positions

HolderShares% AssetsChangeValue
Congress asset management co /ma1.92M0.40%1.92M$57.31M
Norges bank401.50K0.00%401.50K$12.09M
Bridgewater associates, lp342.15K0.05%342.15K$12.36M
Summit financial90.13K0.04%90.13K$2.69M
Nordea investment management ab79.70K0.00%79.70K$2.36M

Sold Out

HolderChange
Global financial private client-2.00
Mendota financial group-4.00
Financial gravity asset management-5.00
Principal securities-6.00
Dinuzzo private wealth-8.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025250-32.98%81,888,299-17.29%561.24%124-19.48%74-43.94%
Sep 30, 2025238-35.68%62,326,392-35.80%420.97%92-50.27%94-7.84%
Jun 30, 2025376-4.08%101,484,9743.38%691.54%187-6.50%105-10.26%
Mar 31, 202539010.48%98,223,5111.40%661.50%2006.38%11620.83%
Dec 31, 2024194-40.49%60,970,728-39.60%420.87%109-42.02%53-28.38%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF8.23M5.18%8.23M
Vanguard Total Stock Mkt Idx Inv4.78M3.01%11.58K
Vanguard US Total Market Shares ETF4.36M2.78%3.80K
iShares Russell 2000 ETF3.50M2.20%620.09K
Vanguard Small Cap Index3.42M2.15%-615.00
State Street® SPDR® S&P® Biotech ETF3.28M2.06%-17.54K
SPDR® S&P Biotech ETF2.30M1.45%5.12K
Vanguard Small Cap Growth Index Inv1.90M1.20%-28.20K
Pictet Biotech1.79M1.16%1.79M
Vanguard Institutional Extnd Mkt Idx Tr1.47M0.92%2.90K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 24, 2025Echelard Yann-Sell$162.85K
Sep 11, 2025Lonial Sagar-Sell$672.27K
Jun 13, 2025Echelard Yann-Sell$369.40K
Jan 03, 2025Power Sean A CFOSell$343.44K
Jan 06, 2025Power Sean A CFOSell$285.94K

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q4-1
2025 Q3-1
2025 Q2-1
2025 Q1-2

TGTX Ownership FAQ


Who Owns TG Therapeutics?

TG Therapeutics shareholders are primarily institutional investors at 56.31%, followed by 7.23% insiders and 36.46% retail investors. The average institutional ownership in TG Therapeutics's industry, Biotech Stocks , is 381.47%, which TG Therapeutics falls below.

Who owns the most shares of TG Therapeutics?

TG Therapeutics’s largest shareholders are Blackrock funding, inc. /de (21.85M shares, 15.02%), Vanguard group (15.84M shares, 10.89%), and Blackrock (11.39M shares, 7.79%). Together, they hold 33.71% of TG Therapeutics’s total shares outstanding.

Does Blackrock own TG Therapeutics?

Yes, BlackRock owns 7.79% of TG Therapeutics, totaling 11.39M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 202.6M$. In the last quarter, BlackRock increased its holdings by 544.84K shares, a 5.02% change.

Who is TG Therapeutics’s biggest shareholder by percentage of total assets invested?

M28 capital management lp is TG Therapeutics’s biggest shareholder by percentage of total assets invested, with 8.58% of its assets in 161.6K TG Therapeutics shares, valued at 5.84M$.

Who is the top mutual fund holder of TG Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of TG Therapeutics shares, with 5.18% of its total shares outstanding invested in 8.23M TG Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools